US Drug Recall Register

FDA Drug Recalls

14,450 recalls · Class II, newest first

Class II · Moderate risk Terminated

AscorbiX

Reason Lack of Assurance of Sterility

Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical NDC 71283-0226-3 D-0939-2020
Class II · Moderate risk Terminated

Alprostadil

Reason Lack of Assurance of Sterility

Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical NDC 71283-0543-2 D-0936-2020
Class II · Moderate risk Terminated

Alprostadil

Reason Lack of Assurance of Sterility

Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical NDC 71283-0538-2 D-0935-2020
Class II · Moderate risk Terminated

Ranitidine 300 mg

Reason CGMP Deviations: Presence of NDMA impurity detected in product.

Direct Rx NDC 61919-455-30 D-0017-2021
Class II · Moderate risk Terminated

Ranitidine 150 mg

Reason CGMP Deviations: Presence of NDMA impurity detected in product.

Direct Rx NDC 61919-339-60 D-0016-2021
Class II · Moderate risk Terminated

Ranitidine Hydrochloride

Reason CGMP Deviations: Presence of NDMA impurity detected in product.

Spectrum Laboratory Products D-0825-2020
Class II · Moderate risk Terminated

Nystatin Oral Suspension

Reason Subpotent: Out of specification for assay at the 12-month time point.

Pharmaceutical Associates Inc NDC 0121-0810-16 D-0824-2020
Class II · Moderate risk Terminated

Testosterone Cypionate for Injection

Reason cGMP Deviations; released lots were manufactured under similar manufacturing conditions to a previously rejected OOS Lot.

Sun Pharmaceutical Industries, Inc. NDC 62756-015-40 D-0788-2020
Class II · Moderate risk Terminated

Testosterone Cypionate for Injection

Reason cGMP Deviations; released lots were manufactured under similar manufacturing conditions to a previously rejected OOS Lot.

Sun Pharmaceutical Industries, Inc. NDC 62756-017-40 D-0787-2020
Class II · Moderate risk Terminated

ranitidine hydrochloride

Reason CGMP Deviations: Received notice from supplier of potential -Nitrosodimethylamine (NDMA) amounts above established levels.

PD-Rx Pharmaceuticals, Inc. NDC 43063-844-14 D-0826-2020
Class II · Moderate risk Terminated

Netspot

Reason Defective Container: loose aluminum cap crimp for the dilution buffer vial present in the NETSPOT Kit (vial 2).

Advanced Accelerator Applications USA, Inc. NDC 69488-001-40 D-0799-2020
Class II · Moderate risk Terminated

Preferred Pharmaceuticals

Reason CGMP Deviations: Presence of NDMA impurity detected in product.

Preferred Pharmaceuticals, Inc D-0797-2020
Class II · Moderate risk Terminated

Preferred Pharmaceuticals

Reason CGMP Deviations: Presence of NDMA impurity detected in product.

Preferred Pharmaceuticals, Inc D-0796-2020
Class II · Moderate risk Terminated

Nizatidine Capsules

Reason CGMP Deviations: Trace amounts of an impurity, N-nitrosodimethylamine (NDMA) was detected in the API Nizatidine.

Mylan Pharmaceuticals Inc. NDC 0378-5300-93 D-0792-2020
Class II · Moderate risk Terminated

Nizatidine Capsules

Reason CGMP Deviations: Trace amounts of an impurity, N-nitrosodimethylamine (NDMA) was detected in the API Nizatidine.

Mylan Pharmaceuticals Inc. NDC 0378-5150-91 D-0791-2020
Class II · Moderate risk Terminated

Dutasteride Capsules

Reason Failed Impurities/Degradation Specifications: High out of specification results for related compounds.

AVKARE Inc. NDC 50268-282-13 D-0661-2020
Class II · Moderate risk Terminated

Ranitidine Capsules 150 mg

Reason CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Appco Pharma LLC NDC 62559-690-60 D-0649-2020
Class II · Moderate risk Terminated

Ranitidine Capsules 300 mg

Reason CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Appco Pharma LLC NDC 62559-691-30 D-0648-2020
Class II · Moderate risk Terminated

Ranitidine

Reason CGMP Deviations: Presence of NDMA impurity detected in product.

H J Harkins Company Inc dba Pharma Pac D-0793-2020